Literature DB >> 7104175

OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.

A W Kelman, B Whiting, S M Bryson.   

Abstract

1 OPT is a series of computer programs designed to assist dose optimisation for individual patients. It is based on Bayesian Statistical Theory and Maximum Likelihood Estimation. 2 OPT uses prior information on the distribution of population pharmacokinetic parameters and plasma drug concentration measurements to obtain the "most likely' set of parameters for the individual. 3 Complex dosage regimes and non-steady state conditions can be handled. 4 OPT is designed for use in a Clinical Pharmacokinetics Laboratory where informed interpretation of results is essential. 5 The drugs for which the system is currently available include theophylline, digoxin, lignocaine, disopyramide, gentamicin and phenytoin (steady state data only).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104175      PMCID: PMC1427763          DOI: 10.1111/j.1365-2125.1982.tb01969.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations.

Authors:  L B Sheiner; H Halkin; C Peck; B Rosenberg; K L Melmon
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

4.  Serum digoxin in adults and children.

Authors:  E Iisalo; M Dahl; H Sundqvist
Journal:  Int J Clin Pharmacol       Date:  1973-04

5.  Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.

Authors:  W J Jusko; M J Gardner; A Mangione; J J Schentag; J R Koup; J W Vance
Journal:  J Pharm Sci       Date:  1979-11       Impact factor: 3.534

6.  The prediction of individual systolic time interval v heart rate regression equations.

Authors:  A W Kelman; D J Sumner; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

7.  Predicting individual phenytoin dosage.

Authors:  S Vozeh; K T Muir; L B Sheiner; F Follath
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

8.  Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

Authors:  S M Bryson; B Whiting; J R Lawrence
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

9.  Disposition kinetics of disopyramide in patients with renal insufficiency.

Authors:  D D Shen; J L Cunningham; I Shudo; D L Azarnoff
Journal:  Biopharm Drug Dispos       Date:  1980 Jan-Mar       Impact factor: 1.627

10.  Disopyramide pharmacokinetics during recovery from myocardial infarction.

Authors:  S M Bryson; C J Cairns; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

  10 in total
  24 in total

1.  Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration.

Authors:  A H Thomson; G Shankland; C Clareburt; S Binning
Journal:  Intensive Care Med       Date:  2002-07       Impact factor: 17.440

Review 2.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 4.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Bayesian individualization via sampling-based methods.

Authors:  J Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

6.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

7.  High-dose melphalan dosage adjustment: possibility of using a test-dose.

Authors:  B Tranchand; Y D Ploin; M P Minuit; C Sapet; P Biron; T Philip; C Ardiet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.

Authors:  S E McKay; C A Howie; A H Thomson; B Whiting; G J Addis
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

Review 9.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 10.  An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics.

Authors:  S M Erdman; K A Rodvold; R D Pryka
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.